Latest Administration News

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

HUB24 has reported record net inflows of $5.6 billion in Q2 FY26, pushing total funds under administration to $152.3 billion and expanding its market share to 9.3%. The company also unveiled a new lifetime retirement solution and an AI-driven adviser ecosystem.

Vinyl Group Ltd has reported a landmark quarter with record cash receipts up 80% quarter-on-quarter and its first operating cash flow positive result, signalling a turning point for the music and culture company.

Telix Pharmaceuticals has achieved a key milestone with China’s NMPA accepting its New Drug Application for Illuccix, a prostate cancer imaging agent backed by strong Phase 3 data. This paves the way for Telix to enter a rapidly growing Chinese market alongside its global approvals.

Pacific Edge reports a 13.4% decline in test volumes for Q3 2026 but gains strategic momentum with a key Medicare advisory meeting and clinical endorsements poised to influence reimbursement policy.

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Phoslock Environmental Technologies has reversed its cashflow deficits with a quarterly surplus, resumed factory operations after a long pause, and is gearing up for significant sales growth in 2026.

PolyNovo reports a robust 26% increase in group sales for 1H FY26, driven by strong U.S. market expansion and a near tripling of NovoSorb MTX sales. The company also completes a new manufacturing facility, positioning itself for sustained growth.

Buru Energy advances its Rafael Gas Project with strong funding interest and a $2.35 million capital raise, setting the stage for critical 2026 drilling and resource validation.

Astron Limited has responded to an ASX query regarding delayed disclosure of director interest changes, attributing the lapse to administrative oversight and outlining steps to tighten compliance.